Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors
Birgit M. Reipert, Pauline M. van Helden, Hans‐Peter Schwarz, et al.
British Journal of Haematology (2006) Vol. 136, Iss. 1, pp. 12-25
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality
John F. Carpenter, Theodore W. Randolph, Wim Jiskoot, et al.
Journal of Pharmaceutical Sciences (2008) Vol. 98, Iss. 4, pp. 1201-1205
Open Access | Times Cited: 548
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw, H. Marijke van den Berg, Johannes Oldenburg, et al.
Blood (2012) Vol. 119, Iss. 12, pp. 2922-2934
Open Access | Times Cited: 329
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
Samantha C. Gouw, H. Marijke van den Berg, Kathelijn Fischer, et al.
Blood (2013) Vol. 121, Iss. 20, pp. 4046-4055
Open Access | Times Cited: 310
Classification and Characterization of Therapeutic Antibody Aggregates
Marisa K. Joubert, Quanzhou Luo, Yasser Nashed-Samuel, et al.
Journal of Biological Chemistry (2011) Vol. 286, Iss. 28, pp. 25118-25133
Open Access | Times Cited: 298
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Marisa K. Joubert, Martha Hokom, Catherine M. Eakin, et al.
Journal of Biological Chemistry (2012) Vol. 287, Iss. 30, pp. 25266-25279
Open Access | Times Cited: 249
Acquired factor VIII inhibitors
Massimo Franchini, Giuseppe Lippi
Blood (2008) Vol. 112, Iss. 2, pp. 250-255
Open Access | Times Cited: 261
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products
John F. Carpenter, Theodore W. Randolph, Wim Jiskoot, et al.
Journal of Pharmaceutical Sciences (2009) Vol. 99, Iss. 5, pp. 2200-2208
Closed Access | Times Cited: 201
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
Jinhai Wang, Jay N. Lozier, Gibbes R. Johnson, et al.
Nature Biotechnology (2008) Vol. 26, Iss. 8, pp. 901-908
Open Access | Times Cited: 159
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy
Jonathan D. Finn, Margareth C. Ozelo, Denise E. Sabatino, et al.
Blood (2010) Vol. 116, Iss. 26, pp. 5842-5848
Open Access | Times Cited: 148
Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
Jan Astermark, Carmen Altisent, Angelika Bátorová, et al.
Haemophilia (2010) Vol. 16, Iss. 5, pp. 747-766
Open Access | Times Cited: 137
Taking immunogenicity assessment of therapeutic proteins to the next level
Isabel Büttel, Paul Chamberlain, Yehuda Chowers, et al.
Biologicals (2011) Vol. 39, Iss. 2, pp. 100-109
Closed Access | Times Cited: 133
Immunogenicity of Protein Pharmaceuticals
Robert Dingman, Sathy V. Balu‐Iyer
Journal of Pharmaceutical Sciences (2018) Vol. 108, Iss. 5, pp. 1637-1654
Open Access | Times Cited: 112
Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues
M. Reza Nejadnik, Theodore W. Randolph, David B. Volkin, et al.
Journal of Pharmaceutical Sciences (2018) Vol. 107, Iss. 8, pp. 2013-2019
Open Access | Times Cited: 91
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high‐responding inhibitors
Antonio Coppola, Maurizio Margaglione, Elena Santagostino, et al.
Journal of Thrombosis and Haemostasis (2009) Vol. 7, Iss. 11, pp. 1809-1815
Open Access | Times Cited: 110
FVIII inhibitors: pathogenesis and avoidance
Jan Astermark
Blood (2015) Vol. 125, Iss. 13, pp. 2045-2051
Open Access | Times Cited: 88
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence‐based approaches
Antonio Coppola, Matteo Nicola Dario Di Minno, Elena Santagostino
British Journal of Haematology (2010) Vol. 150, Iss. 5, pp. 515-528
Closed Access | Times Cited: 87
Review of immune tolerance induction in hemophilia A
Sarah J. Schep, Roger E. G. Schutgens, Kathelijn Fischer, et al.
Blood Reviews (2018) Vol. 32, Iss. 4, pp. 326-338
Closed Access | Times Cited: 64
IgG subclasses of anti‐FVIII antibodies during immune tolerance induction in patients with hemophilia A
Pauline M. van Helden, H. Marijke van den Berg, Samantha C. Gouw, et al.
British Journal of Haematology (2008) Vol. 142, Iss. 4, pp. 644-652
Open Access | Times Cited: 93
T‐cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self‐peptide
Eddie A. James, William W. Kwok, Ruth A. Ettinger, et al.
Journal of Thrombosis and Haemostasis (2007) Vol. 5, Iss. 12, pp. 2399-2407
Open Access | Times Cited: 80
Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response
Braden Waters, Mohammad Qadura, Erin Burnett, et al.
Blood (2008) Vol. 113, Iss. 1, pp. 193-203
Open Access | Times Cited: 78
Immune tolerance in haemophilia: the long journey to the fork in the road
Donna DiMichele
British Journal of Haematology (2012) Vol. 159, Iss. 2, pp. 123-134
Open Access | Times Cited: 59
Shear stress as a driver of degradation for protein-based therapeutics: More accomplice than culprit
Camilla Moino, Fiora Artusio, Roberto Pisano
International Journal of Pharmaceutics (2023) Vol. 650, pp. 123679-123679
Open Access | Times Cited: 15
A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic
Joseph R. Cohen, Stephen R. Brych, Siddharth Prabhu, et al.
Pharmaceutical Research (2024) Vol. 41, Iss. 4, pp. 651-672
Closed Access | Times Cited: 5
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice
P. C. TER AVEST, Kathelijn Fischer, Maria Elisa Mancuso, et al.
Journal of Thrombosis and Haemostasis (2008) Vol. 6, Iss. 12, pp. 2048-2054
Open Access | Times Cited: 72
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
J Somerfield, Grant Hill-Cawthorne, Andrew C. Lin, et al.
The Journal of Immunology (2010) Vol. 185, Iss. 1, pp. 763-768
Closed Access | Times Cited: 65
Page 1 - Next Page

Scroll to top